2026-04-02
Myeloid Cure Completes Over RMB 150 Million Series A Financing, Deepens Original Drug Development in Macrophage Immunotherapy
Myeloid Cure Biotechnology Co., Ltd. ("Myeloid Cure") announced the completion of its over RMB 150 million Series A financing. The round is led by Bayland Capital, with participation from Hongfeng Investment, Ruihua Capital, leading industry investment institutions and prominent industrial funds.
2022-09-13
Dedicated to Novel Target and Drug R&D, China’s First Innovative Biopharma Focused on Macrophages Myeloid Cure Completes Another Tens of Millions of RMB Financing
Myeloid Cure Biotechnology Co., Ltd. recently announced the completion of a new round financing of tens of millions of RMB. Myeloid Cureis the pioneer emerging biotechnology enterprise focusing on the development of biopharmaceuticals with new targets for macrophages in the tumor microenvironment and autoimmune diseases in China
2021-06-21
Myeloid Cure announced the completion of an angel round of financing of tens of millions of RMB
Myeloid Cure is the pioneer domestic emerging biotechnology enterprise in China focusing on the development of new target drugs for macrophages. Immunotherapy drugs are currently the most important treatments for cancers and autoimmune diseases,